Stay updated on Johnson & Johnson Press Releases

Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Johnson & Johnson Press Releases page

  1. Check
    4 days ago
    Change Detected
    Summary
    Johnson & Johnson is set to license a novel oral asset targeting atopic dermatitis, enhancing its commitment to innovative treatments, while the previous report on DARZALEX FASPRO® and its efficacy in multiple myeloma has been removed.
    Difference
    21%
    Check dated 2024-12-29T15:40:28.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The website has added significant updates including Johnson & Johnson's application to the European Medicines Agency for IMBRUVICA® in treating untreated mantle cell lymphoma, and their participation in the WHO Academy inauguration to enhance global health worker training, while also seeking FDA approval for SIMPONI® in pediatric ulcerative colitis.
    Difference
    100%
    Check dated 2024-12-22T08:09:22.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Recent updates highlight significant advancements in pediatric cardiac care with the FDA's expanded indication for Impella heart pumps, promising results from CARVYKTI® in multiple myeloma, and ongoing research into targeted treatments for warm autoimmune hemolytic anemia, while notable deletions include the FDA approval of larger breast implants and various hematology-related presentations.
    Difference
    100%
    Check dated 2024-12-15T00:24:48.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The website has added significant updates including the FDA approval of the MENTOR™ MemoryGel™ Enhance Breast Implant for larger sizes, and applications for TREMFYA® to treat pediatric psoriasis and psoriatic arthritis, while also noting a slight increase in search results from 2,068 to 2,071.
    Difference
    100%
    Check dated 2024-12-07T21:56:23.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Recent updates highlight the U.S. FDA's approval of TREMFYA® for ulcerative colitis, marking it as a potential first for IL-23 inhibitors, alongside significant advancements in hematology and psoriasis treatments showcased at upcoming medical congresses.
    Difference
    100%
    Check dated 2024-11-23T05:54:35.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Notable updates include the CHMP's recommendation of RYBREVANT® for advanced non-small cell lung cancer and significant clinical improvements demonstrated by nipocalimab in Sjögren’s disease, which has received FDA Breakthrough Therapy Designation.
    Difference
    100%
    Check dated 2024-11-16T01:40:53.000Z thumbnail image

Stay in the know with updates to Johnson & Johnson Press Releases

Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.